10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2016 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2016 10-K (Filed: Feb 27, 2017) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | |
| Operating Activities: | |||
| Net income | $ 13,488 | 18,106 | 12,059 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation expense | 177 | 161 | 125 |
| Amortization expense | 981 | 937 | 925 |
| Stock-based compensation expense | 380 | 382 | 360 |
| Excess tax benefits from stock-based compensation | (194) | (585) | (482) |
| Tax benefits from exercise and vesting of stock-based awards | 186 | 586 | 484 |
| Deferred income taxes | (119) | (393) | (236) |
| In-process research and development impairment | 432 | 0 | 0 |
| Other | (24) | (24) | 101 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | 1,192 | (1,397) | (2,578) |
| Inventories | (488) | (855) | 143 |
| Prepaid expenses and other | (520) | (90) | (371) |
| Accounts payable | 47 | 226 | (289) |
| Income taxes payable | 1,010 | 269 | 533 |
| Accrued liabilities | 425 | 2,632 | 2,013 |
| Deferred revenues | (304) | 374 | 31 |
| Net cash provided by operating activities | 16,669 | 20,329 | 12,818 |
| Investing Activities: | |||
| Purchases of marketable securities | (25,619) | (17,239) | (2,107) |
| Proceeds from sales of marketable securities | 13,039 | 4,792 | 807 |
| Proceeds from maturities of marketable securities | 1,700 | 719 | 52 |
| Other investments | (357) | 0 | (18) |
| Capital expenditures | (748) | (747) | (557) |
| Net cash used in investing activities | (11,985) | (12,475) | (1,823) |
| Financing Activities: | |||
| Proceeds from debt financing, net of issuance costs | 5,293 | 9,902 | 7,932 |
| Proceeds from convertible note hedges | 956 | 784 | 2,543 |
| Purchases of convertible note hedges | 0 | 0 | (26) |
| Proceeds from issuances of common stock | 208 | 319 | 331 |
| Repurchases of common stock | (11,001) | (10,002) | (5,349) |
| Repayments of debt and other obligations | (1,981) | (997) | (4,779) |
| Payments to settle warrants | (469) | (3,865) | (4,093) |
| Excess tax benefits from stock-based compensation | 194 | 585 | 482 |
| Payment of contingent consideration | (2) | (3) | (101) |
| Payment of dividends | (2,455) | (1,874) | 0 |
| Contributions from (distribution to) noncontrolling interest | (90) | 188 | 35 |
| Net cash used in financing activities | (9,347) | (4,963) | (3,025) |
| Effect of exchange rate changes on cash and cash equivalents | 41 | (67) | (56) |
| Net change in cash and cash equivalents | (4,622) | 2,824 | 7,914 |
| Cash and cash equivalents at beginning of period | 12,851 | 10,027 | |
| Cash and cash equivalents at end of period | 8,229 | 12,851 | 10,027 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid, net of amounts capitalized | 885 | 529 | 330 |
| Income taxes paid | 2,436 | 3,137 | 2,060 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2016 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |